Background. Healthcare-associated infections due to multiply-resistant organisms cause significant morbidity and mortality in acute care settings. Antimicrobial stewardship programs (ASP) are one practice used to limit resistance and are especially crucial given the lack of new antimicrobials in development. The aim of this study was to describe the presence of ASP in a national sample of acute care hospitals and examine the engagement of Infection Preventionists (IPs) in antimicrobial stewardship activities.
Background. In July 2016, the FDA updated its boxed warning for fluoroquinolones (FQ) in light of ongoing safety concerns. Our objective was to examine trends in FQ and other antibiotic prescribing before and after the warning.
Methods. We analyzed electronic health records for inpatient, outpatient, and emergency department encounters during April 2014-August 2017 in the University of North Carolina Health Care System (N = 14,524,758 encounters). Patients under age 2 years were excluded. We estimated FQ prescribing rates per 1,000 encounters (henceforth, "/1,000"). Using an interrupted time series approach, we fit segmented linear regression models to assess trends before and after the FDA warning, accounting for seasonality and autocorrelated errors. We evaluated trends by gender, age, and point of care, and explored potential replacement of FQs by other antibiotics after the warning.
Results. The average FQ prescribing rate was 9.2/1,000 (95% CI 3.8, 14.7). Before the warning (April 2014-July 2016), the FQ prescribing rate decreased by 0.6/1,000/year (95% CI 0.3, 0.9) (figure). At the time of the warning, the slope for the FQ prescribing rate steepened by 0.8/1,000/year (95% CI −0.1, 1.7); as a result, after the warning (July 2016-August 2017), the rate decreased by 1.4/1,000/year (95% CI 0.7, 2.1). FQ prescribing was most common among adults age ≥65 (mean rate 12.2/1,000), but relative trends were similar across age and gender. Average FQ prescribing rates were highest in the inpatient setting (40.5/1,000) compared with emergency (18.3/1,000) and outpatient (6.2/1,000) encounters; relative trends were similar across settings. Rates for other common antibiotics did not increase after the warning, either overall (figure) or in any subgroup. Results were robust to sensitivity analysis for lagged effects. Additionally, the interpretation of results is anchored by trends for inhaled corticosteroids, which we analyzed as a negative control (figure).
Conclusion. The July 2016 FDA warning on FQs was associated with a small deceleration in FQ prescribing. There was no evidence of replacement by antibiotics with similar indications. We observed no evidence of heterogeneity across subgroups defined by gender, age, and point of care. Future research should assess the potential impact of the warning in clinically defined subgroups in various settings. Methods. With support from VA Antimicrobial Stewardship Task Force and NHSN, we deployed one team to focus on implementation and another on technical aspects. We used an iterative recruitment approach with four cohorts to date (Tiers), starting with highly engaged facilities with strong stewardship infrastructure. Our implementation approach (Figure 1 ) was based on the Promoting Action on Research Implementation (PARiHS) framework for successful implementation of evidence into clinical practice. We evaluated our implementation with focus groups conducted using Skype chat to collect feedback from participants about the implementation process. Group 1 contained six participants from Tiers 1 and 2. Group 2 had three participants from Tiers 3 and 4. Questions were constructed using the PARiHS framework (Table 1 ). An implementation team member conducted interviews, monitored the discussion, then coded major themes of responses.
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Results. To date, there are over 90 facilities reporting AU to NHSN. Major themes to responses are summarized in Table 1 . Overall, focus group participants were supportive of the program, but there were differences between early and later adopters.
Conclusion. A coordinated, centralized approach to facilitating implementation of NHSN AU reporting has been successful so far. Major themes from focus group responses did differ in some categories depending on tier in a way that appears concordant with the theory diffusion of innovation, e.g., early tiers were enthusiastic despite a lack of institutional support while later tiers reported being motivated by regulatory requirements and had solid institutional support. More research would further inform how to efficiently implement complex programs in large systems.
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No reported disclosures. Background. Urinary tract infections (UTIs) are among the most commonly treated infections in the Emergency Department (ED). Treatment is largely empiric and based on an institution-wide antibiogram comprised of isolates from all infection sites, which may overestimate antibiotic resistance of urinary pathogens of nonadmitted ED patients. The primary goal of this study was to determine the antibiotic susceptibilities of urinary pathogens isolated from adult patients with a UTI and discharged from the ED.
Antibiotic Susceptibilities of Organisms Isolated from Urine Cultures of
Methods. This was a single-center, retrospective chart review of adult patients discharged from the ED with a UTI from August to December 2017. Descriptive statistics were used to compare the antibiotic susceptibilities of pathogens isolated from urine cultures to the institutional and local Brooklyn antibiogram. Antibiotic susceptibilities were determined by MicroScan. Data on antibiotic prescribing patterns and previously described risk factors for multidrug-resistant organisms were collected.
Results. Two hundred forty-six patients were included with 267 isolates identified. 61% (151) of patients were between ages 18 to 65 years old and 73% (180) were female.
The most common organism isolated was Escherichia coli (164, 62%). E. coli urine isolates were most susceptible to nitrofurantoin (98%) followed by cefazolin (81%), ciprofloxacin (84%), and sulfamethoxazole/trimethoprim (64%). There was no difference in susceptibility rates of E. coli to cefazolin or sulfamethoxazole/trimethoprim, but isolates were more susceptible to ciprofloxacin in the ED compared with the institutional antibiogram (84% vs. 70%). Twenty-six (10.6%) patients grew an ESBL organism and of these, 42% (11/26) had no identifiable healthcare exposure within the last 90 days.
Conclusion. Despite limitations in sample size, this study supports using separate antibiograms and pathways for the treatment of UTI in the ED, especially in a community with high rates of local resistance to first-line agents.
Disclosures. October 6, 2018: 12:30 PM Background. Hospital admissions due to acute decompensated heart failure (ADHF) are common, and the clinical presentation can be confused with other conditions such as pneumonia. Hospitalized ADHF patients often receive antibiotic therapy even when the clinical suspicion for pneumonia is low, and intravenous (IV) antibiotics are commonly used. We hypothesized the additional fluid and sodium content of potentially unnecessary antibiotic therapy could worsen outcomes and complicate management of ADHF patients.
Methods. We conducted a retrospective cohort analysis of adult patients with a diagnosis of ADHF. Patients were excluded if chest radiography suggested pneumonia, if they were continuing a prior antibiotic regimen, if they were diagnosed with a proven infection during admission, or if serum BNP level was not elevated. Patients who received antibiotics were compared with those who did not with respect to diuretic requirements, length of stay, sodium and fluid load attributable to antibiotic treatment, and readmission rate.
Results. Three hundred thirty-seven patients were screened for inclusion of which 153 were enrolled, 89 in the nonantibiotic arm compared with 64 in the antibiotic arm. Median length of stay in the antibiotic arm was 6.5 days as opposed to 3.25 days in the nonantibiotic arm (P < 0.001). The antibiotic group received a median dosage of 1,000 mg of furosemide compared with 400 mg in the nonantibiotic arm (P < 0.001). Patients who received antibiotics were 2.51 times more likely to be readmitted compared with patients who did not receive antibiotics (P = 0.04). On average, each patient in the antibiotic arm received approximately 970 mg of sodium daily and 1.6 L of volume attributed to antibiotic infusions.
Conclusion. Patients who received IV antibiotics during treatment for ADHF without evidence of infection had significantly longer lengths of stay, received significantly higher doses of furosemide, and were more likely to be readmitted compared with patients with the same diagnosis who were not exposed to intravenous antibiotics. Additional studies are needed to determine factors contributing to potential overprescribing in this population, and ADHF patients are a promising target of antibiotic stewardship interventions.
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